ЛЕКАРСТВЕННОЕ ПОРАЖЕНИЕ ПОЧЕК У БОЛЬНЫХ ВИЧ-ИНФЕКЦИЕЙ: КЛИНИЧЕСКИЕ ВАРИАНТЫ, ВОЗМОЖНОСТИ ПРЕДУПРЕЖДЕНИЯ


Цитировать

Полный текст

Аннотация

Обсуждается поражение почек, в том числе связанное с высокоактивной антиретровирусной терапией, у больных ВИЧ-инфекцией; его клинические варианты (острая почечная недостаточность, канальцевые дисфункции), подходы к диагностике и профилактике.

Об авторах

Н А Мухин

ГОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития России

ГОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития России

В В Фомин

ГОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития России

ГОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития России

Список литературы

  1. Winston J.A. HIV and CKD epidemiology. Adv. Chronic Kidney Dis. 2010; 17(1): 19-25
  2. Gupta S.K., Eustace J.A., Winston J.A. et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: Recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin. Infect. Dis. 2005; 40: 1559-1585
  3. Berns J.S., Kasbekar N. Highly active antiretroviral therapy and the kidney: and update on antiretroviral medications for nephrologists. Clin. J. Am. Soc. Nephrol. 2006; 1: 117-129
  4. Perazella M.A. Acute renal failure in HIV-infected patients: a brief review of common causes. Am. J. Med. Sci. 2000; 319(6): 385-391
  5. Izzedine H., Baumelou A., Deray G. Acute renal failure in HIV patients. Nephrol. Dial. Transplant. 2007; 22: 2757 - 2762
  6. Franceschini N., Napravnik S., Eron J.J. et al. Incidence and etiology of acute renal failure among ambulatory HIV-infected patients. Kidney Int. 2005; 67: 1526 - 1531
  7. Wyatt C.M., Arons R.R., Klotman P.E., Klotman M.E. Acute renal failure in hospitalized patients with HIV: risk factors and impact on in-hospital mortality. AIDS 2006; 204561 - 204565
  8. Peraldi M.N., Maslo C., Akposso K. et al. Acute renal failure in the course of retrospective study of ninety-two patients and sixty renal biopsies. Nephrol. Dial. Transplant. 1999; 14(6): 1578-1585.
  9. Nicolau Laparra M.C., Martínez F., Giner V. et al. Temporal evolution of renal involvement in a necropsy study of HIV patients from the pre and HAART eras. Nefrologia. 2010; 30(4): 420-426
  10. Joshi M.K., Liu H.H. Acute rhabdomyolysis and renal failure in HIV-infected patients: risk factors, presentation, and pathophysiology. AIDS Patient Care STDS. 2000; 14(10): 541-548
  11. Roe J., Campbell L.J., Ibrahim F. et al. HIV care and the incidence of acute renal failure. Clin. Infect. Dis. 2008; 47(2): 242-249
  12. Overton E.T., Nurutdinova D., Freeman J. et al. Factors associated with renal dysfunction within an urban HIV-infected cohort in the era of highly active antiretroviral therapy. HIV Med. 2009; 10(6): 343-350
  13. Ibrahim F., Naftalin C., Cheserem E. et al. Immunodeficiency and renal impairment are risk factors for HIV-associated acute renal failure. AIDS. 2010; 24(14): 2239-2244
  14. Crum-Cianflone N., Ganesan A., Teneza-Mora N. et al. Prevalence and factors associated with renal dysfunction among HIV-infected patients. AIDS Patient Care STDS. 2010; 24(6): 353-360
  15. Izzedine H., Hulot J.S., Vittecoq D. et al. Study 903 Team. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol. Dial. Transplant. 2005; 20: 743 - 746
  16. Barrios A., García-Benayas T., González-Lahoz J., Soriano V. Tenofovir-related nephrotoxicity in HIV-infected patients. AIDS. 2004; 18(6): 960-963
  17. Gallant J.E., Winston J.A., DeJesus E. et al. The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients. AIDS. 2008; 22(16): 2155-2163
  18. Mauss S., Berger F., Schmutz G. Antiretroviral therapy with tenofovir is associated with mild renal dysfunction. AIDS 2005; 19: 93-95
  19. Madeddu G., Bonfanti P., De Socio G.V. et al.; CISAI Group. Tenofovir renal safety in HIV-infected patients: results from the SCOLTA Project. Biomed. Pharmacother. 2008; 62(1): 6-11
  20. Jones R., Wolf E., Hoffmann C., Procaccianti M. et al. Long-term consequences of treatment interruptions in chronically HIV-1 infected patients. Eur. J. Med. Res. 2005; 10(2): 56-62
  21. Jones R., Stebbing J., Nelson M. et al. Renal dysfunction with tenofovir DF containing HAART regimens is not observed more frequently: a cohort and case-control study. J. AIDS 2001; 37: 1489 - 1495
  22. Psevdos G. Jr., Gonzalez E., Sharp V. Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis. AIDS Read. 2009; 19(6): 245-248
  23. Riordan A., Judd A., Boyd K. et al.; Collaborative HIV Paediatric Study. Tenofovir use in human immunodeficiency virus-1-infected children in the United Kingdom and Ireland. Pediatr. Infect. Dis. J. 2009; 28(3): 204-209
  24. Bpharm S.M., Talbot A., Trottier B. et al. Acute renal failure in four HIV-infected patients: Potential association with tenofovir and nonsteroidal anti-inflammatory drugs. Can. J. Infect. Dis. Med. Microbiol. 2008; 19(1): 75-76
  25. Izzedine H., Launay-Vacher V., Deray G. Renal tubular transporters and antiviral drugs: an update. AIDS 2005; 19: 455 - 462
  26. Quimby D., Brito M.O. Fanconi syndrome associated with use of tenofovir in HIV-infected patients: a case report and review of the literature. AIDS Read. 2005; 15(7): 357-364
  27. Badiou S., De Boever C.M., Terrier N. et al. Is tenofovir involved in hypophosphatemia and decrease in tubular prosphate reabsorbtion in HIV-positive adults? J. Infect. 2006; 52: 335-338
  28. Harmouche H., Le Bras P., Bignani O. et al. Acute renal failure, Fanconi syndrome and insipidus diabetes in a HIV-infected patient treated with Tenofovir. Rev. Med. Interne. 2005; 26(6): 522-523
  29. Callens S., De Roo A., Colebunders R. Fanconi-like syndrome and rhabdomyolysis in a person with HIV infection on highly active antiretroviral treatment including tenofovir. J. Infect. 2003; 47(3): 262-263
  30. D'Ythurbide G., Goujard C., Méchaï F. et al. Fanconi syndrome and nephrogenic diabetes insipidus associated with didanosine therapy in HIV infection: a case report and literature review. Nephrol. Dial. Transplant. 2007; 22(12): 3656-3659
  31. de la Prada F.J., Prados A.M., Tugores A. et al. Acute renal failure and proximal renal tubular dysfuntion in a patient with acquired immunodeficiency syndrome treated with tenofovir. Nefrologia. 2006; 26(5): 626-630
  32. Hall A.M., Hendry B.M., Nitsch D., Connolly J.O. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am. J. Kidney Dis. 2011; 57(5): 773-780
  33. Gatanaga H., Tachikawa N., Kikuchi Y. et al. Urinary beta2-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate. AIDS Res. Hum. Retroviruses. 2006; 22(8): 744-748
  34. Izzedine H., Launay-Vacher V., Aymard G. et al. Pharmacokinetics of abacavir in HIV-1-infected patients with impaired renal function. Nephron. 2001; 89(1): 62-67
  35. Post F.A., Moyle G.J., Stellbrink H.J. et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT Study. J. Acquir. Immune Defic. Syndr. 2010; 55(1): 49-57

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах